NMD Pharma's Ignaseclant Shows Promise in Phase 2a Trial for Charcot-Marie-Tooth Disease
核心洞察
NMD Pharma (搜索)'s Phase 2a SYNAPSE-CMT (搜索) study of ignaseclant (搜索) demonstrated consistent improvements in muscle strength, motor performance, and patient-reported outcomes in 81 patients with Charcot-Marie-Tooth disease (搜索) types 1 and 2.
The first-in-class ClC-1 (搜索) inhibitor showed robust improvements in handgrip strength and fine hand function, with benefits maintained through day 28 even after treatment discontinuation.
Although the primary endpoint of 6-minute walk test was not met, the favorable safety profile and functional improvements support accelerated clinical development for this orphan disease with no approved therapies.
NMD Pharma (搜索) A/S announced positive topline results from its Phase 2a SYNAPSE-CMT (搜索) study evaluating ignaseclant (搜索), a first-in-class small molecule inhibitor of the skeletal muscle-specific chloride ion channel 1 (搜索) (ClC-1 (搜索)), in patients with Charcot-Marie-Tooth disease (搜索) (CMT) types 1 and 2. The exploratory study demonstrated consistent and clinically meaningful functional improvements across multiple measures of muscle strength, motor performance, and patient-reported outcomes, despite missing its primary endpoint.
Study Design and Patient Population
The SYNAPSE-CMT (搜索) trial (NCT06482437) was a randomized, double-blind, placebo-controlled Phase 2a study that enrolled 81 adult patients with genetically confirmed CMT1 or CMT2 subtypes across clinical sites in the US and Europe. Patients received twice-daily oral ignaseclant (搜索) for 21 days, with follow-up assessments conducted at day 28.
While the study did not demonstrate a treatment difference on the 6-minute walk test (6MWT) at 21 days—the pre-specified primary endpoint—patients receiving ignaseclant (搜索) showed improvements across multiple pre-specified secondary endpoints that are recognized as highly relevant by the CMT (搜索) clinical and patient community.
Key Clinical Findings
The study revealed several encouraging results across both CMT1 and CMT2 patient populations. Patients demonstrated improvements on the validated Charcot-Marie-Tooth Functional Outcome Measure (CMT (搜索)-FOM), a composite scale assessing strength and function across multiple domains, with separation from placebo observed during treatment and maintained through day 28.
Particularly notable were robust improvements in handgrip strength, identified as a clinically meaningful domain for patients with CMT (搜索). The study also showed improvements in fine hand function, supporting functional benefit beyond gross motor performance. Patient-reported improvements in physical function and disease impact, as measured by the CMT-Health Index (CMT-HI), aligned with objective functional findings.
Importantly, functional gains were maintained following treatment discontinuation, suggesting effects that extend beyond short-acting pharmacologic muscle activation.
Safety Profile
Ignaseclant (搜索) demonstrated a favorable safety profile throughout the study. All reported adverse events were mild or moderate and did not require drug discontinuation. No serious adverse events were reported by patients receiving ignaseclant, and the observed safety profile was consistent with prior clinical experience.
Expert Commentary
"There are currently no approved therapies for people with CMT (搜索), and it is encouraging to see improvement trajectories across multiple measures of muscle strength and function in a short clinical study," said Dr. David Herrmann, MBBCh, Chief of the Neuromuscular Division in the Department of Neurology at the University of Rochester Medical Center and CMT-SYNAPSE study investigator. "The improvements observed in hand strength and dexterity are particularly relevant for patients, as these functions directly affect daily activities. These findings support further evaluation of ignaseclant (搜索) in longer-duration studies."
Professor Mary Reilly, MD, Head of Division of Clinical Neurology, UCL Queen Square Institute of Neurology, added: "As there are no current approved treatments for any form of CMT (搜索), a study such as this current Phase 2a trial of ignaseclant (搜索) in both CMT1 and CMT2 is very welcome. The results from this exploratory study suggest that targeting skeletal muscle excitability may improve both muscle strength and function in CMT."
Mechanism of Action and Development Pipeline
Ignaseclant (搜索) works by inhibiting ClC-1 (搜索), which enhances skeletal muscle excitability and the muscle's responsiveness to weak signals, improving neuromuscular transmission and restoring muscle activation and skeletal muscle function. The drug has previously demonstrated clinically meaningful improvements in a Phase 1b/2a study in generalized myasthenia gravis (搜索) (gMG), published in Science Translational Medicine.
Ana de Vera, MD, Chief Medical Officer at NMD Pharma (搜索), commented: "These Phase 2a clinical study results provide encouraging evidence that ignaseclant (搜索) positively impacts skeletal muscle strength and function within weeks of treatment initiation, with effects that appear to persist beyond the dosing period. Importantly, we did not observe a plateau at the end of the treatment window, suggesting the potential for further benefit with longer-duration therapy."
Regulatory Status and Future Plans
In January 2025, the U.S. Food and Drug Administration granted Orphan Drug Designation to ignaseclant (搜索) for the treatment of CMT (搜索). NMD Pharma (搜索) plans to submit detailed topline data from SYNAPSE-CMT as a late breaking abstract or presentation at a leading neuromuscular scientific meeting in the first half of 2026 and to publish the full study results in a peer-reviewed journal.
The company is also conducting a Phase 2a study in adults with spinal muscular atrophy (搜索) (SMA) and a Phase 2b study in gMG with AChR and MuSK positive autoantibodies, with topline results expected in the first half and second half of 2026, respectively.
Disease Background
CMT (搜索) is a rare, inheritable neuromuscular disease affecting approximately one in 2,500 people worldwide, including an estimated 135,000 individuals in the United States, making it one of the most prevalent rare orphan neuromuscular diseases. The condition causes progressive dysfunction of peripheral nerves, leading to sensory loss, debilitating muscle weakness, impaired balance, declining motor control and substantial limitations in daily function that typically worsen over time.
Currently, there are no FDA-approved treatments for CMT (搜索), and patient care is supportive, relying on physical therapy, orthotic devices, and mobility aids. The significant and lifelong burden of CMT underscores the urgent need for new therapeutic approaches.